Immunotherapy response evaluation with magnetic resonance elastography (MRE) in advanced HCC

Aliya Qayyum, Ken Pin Hwang, Jason Stafford, Anuj Verma, Dipen M. Maru, Subramanya Sandesh, Jia Sun, Roberto Carmagnani Pestana, Rony Avritscher, Manal M. Hassan, Hesham Amin, Asif Rashid, Ignacio I. Wistuba, Richard L. Ehman, Jingfei Ma, Ahmed O. Kaseb

Research output: Contribution to journalArticle

Abstract

Background: Currently, there are no imaging predictors of immunotherapy outcome in hepatocellular carcinoma (HCC). The study aim was to determine if stiffness changes measured by magnetic resonance elastography (MRE) can be a predictor of immunotherapy response in patients with advanced HCC. Materials and methods: This was a prospective study of 15 patients with biopsy proven-advanced HCC treated with Pembrolizumab. All patients had liver MRE and liver biopsy at baseline and at 6 weeks of therapy. Change in HCC stiffness on MRE was compared with overall survival (OS), time to disease progression (TTP), and number of intratumoral CD3+ T lymphocytes. Analysis was performed using descriptive statistics and Spearman correlation (R); p-value < 0.05 was considered statistically significant. Results: Nine patients were evaluable. Median age was 71 years (range, 54-78). Etiology of liver disease was HCV (n = 4), HBV (n = 1) and NASH (n = 4). Median OS and TTP were 44 weeks and 13 weeks, respectively. Average baseline HCC stiffness and change in HCC stiffness were 5.0 kPa and 0.12 kPa, respectively. In contrast, average non-tumor liver stiffness was 3.2 kPa, and did not significantly change at 6 weeks (p = 0.42). Average size of measured tumor and change in size were 4 cm and - 0.32 cm, respectively. Change in HCC stiffness at 6 weeks correlated significantly with OS (R = 0.81), and TTP (R = 0.88,p < 0.01). Abundance of intratumoral T lymphocytes on tumor biopsy correlated significantly with HCC stiffness (R = 0.79,p = 0.007). Conclusion: Our pilot MRE data suggests early change in tumor stiffness may be an indicator of immunotherapy response in patients with advanced HCC.

Original languageEnglish (US)
Article number329
JournalJournal for ImmunoTherapy of Cancer
Volume7
Issue number1
DOIs
StatePublished - Nov 28 2019

Fingerprint

Elasticity Imaging Techniques
Immunotherapy
Hepatocellular Carcinoma
Disease Progression
Biopsy
Survival
Liver
T-Lymphocytes
Neoplasms
Liver Diseases
Prospective Studies

Keywords

  • Hepatocellular carcinoma
  • Immunotherapy
  • Magnetic resonance Elastopgraphy

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Molecular Medicine
  • Oncology
  • Pharmacology
  • Cancer Research

Cite this

Qayyum, A., Hwang, K. P., Stafford, J., Verma, A., Maru, D. M., Sandesh, S., ... Kaseb, A. O. (2019). Immunotherapy response evaluation with magnetic resonance elastography (MRE) in advanced HCC. Journal for ImmunoTherapy of Cancer, 7(1), [329]. https://doi.org/10.1186/s40425-019-0766-y

Immunotherapy response evaluation with magnetic resonance elastography (MRE) in advanced HCC. / Qayyum, Aliya; Hwang, Ken Pin; Stafford, Jason; Verma, Anuj; Maru, Dipen M.; Sandesh, Subramanya; Sun, Jia; Pestana, Roberto Carmagnani; Avritscher, Rony; Hassan, Manal M.; Amin, Hesham; Rashid, Asif; Wistuba, Ignacio I.; Ehman, Richard L.; Ma, Jingfei; Kaseb, Ahmed O.

In: Journal for ImmunoTherapy of Cancer, Vol. 7, No. 1, 329, 28.11.2019.

Research output: Contribution to journalArticle

Qayyum, A, Hwang, KP, Stafford, J, Verma, A, Maru, DM, Sandesh, S, Sun, J, Pestana, RC, Avritscher, R, Hassan, MM, Amin, H, Rashid, A, Wistuba, II, Ehman, RL, Ma, J & Kaseb, AO 2019, 'Immunotherapy response evaluation with magnetic resonance elastography (MRE) in advanced HCC', Journal for ImmunoTherapy of Cancer, vol. 7, no. 1, 329. https://doi.org/10.1186/s40425-019-0766-y
Qayyum, Aliya ; Hwang, Ken Pin ; Stafford, Jason ; Verma, Anuj ; Maru, Dipen M. ; Sandesh, Subramanya ; Sun, Jia ; Pestana, Roberto Carmagnani ; Avritscher, Rony ; Hassan, Manal M. ; Amin, Hesham ; Rashid, Asif ; Wistuba, Ignacio I. ; Ehman, Richard L. ; Ma, Jingfei ; Kaseb, Ahmed O. / Immunotherapy response evaluation with magnetic resonance elastography (MRE) in advanced HCC. In: Journal for ImmunoTherapy of Cancer. 2019 ; Vol. 7, No. 1.
@article{18b025148d73409b8dafea5f62af9397,
title = "Immunotherapy response evaluation with magnetic resonance elastography (MRE) in advanced HCC",
abstract = "Background: Currently, there are no imaging predictors of immunotherapy outcome in hepatocellular carcinoma (HCC). The study aim was to determine if stiffness changes measured by magnetic resonance elastography (MRE) can be a predictor of immunotherapy response in patients with advanced HCC. Materials and methods: This was a prospective study of 15 patients with biopsy proven-advanced HCC treated with Pembrolizumab. All patients had liver MRE and liver biopsy at baseline and at 6 weeks of therapy. Change in HCC stiffness on MRE was compared with overall survival (OS), time to disease progression (TTP), and number of intratumoral CD3+ T lymphocytes. Analysis was performed using descriptive statistics and Spearman correlation (R); p-value < 0.05 was considered statistically significant. Results: Nine patients were evaluable. Median age was 71 years (range, 54-78). Etiology of liver disease was HCV (n = 4), HBV (n = 1) and NASH (n = 4). Median OS and TTP were 44 weeks and 13 weeks, respectively. Average baseline HCC stiffness and change in HCC stiffness were 5.0 kPa and 0.12 kPa, respectively. In contrast, average non-tumor liver stiffness was 3.2 kPa, and did not significantly change at 6 weeks (p = 0.42). Average size of measured tumor and change in size were 4 cm and - 0.32 cm, respectively. Change in HCC stiffness at 6 weeks correlated significantly with OS (R = 0.81), and TTP (R = 0.88,p < 0.01). Abundance of intratumoral T lymphocytes on tumor biopsy correlated significantly with HCC stiffness (R = 0.79,p = 0.007). Conclusion: Our pilot MRE data suggests early change in tumor stiffness may be an indicator of immunotherapy response in patients with advanced HCC.",
keywords = "Hepatocellular carcinoma, Immunotherapy, Magnetic resonance Elastopgraphy",
author = "Aliya Qayyum and Hwang, {Ken Pin} and Jason Stafford and Anuj Verma and Maru, {Dipen M.} and Subramanya Sandesh and Jia Sun and Pestana, {Roberto Carmagnani} and Rony Avritscher and Hassan, {Manal M.} and Hesham Amin and Asif Rashid and Wistuba, {Ignacio I.} and Ehman, {Richard L.} and Jingfei Ma and Kaseb, {Ahmed O.}",
year = "2019",
month = "11",
day = "28",
doi = "10.1186/s40425-019-0766-y",
language = "English (US)",
volume = "7",
journal = "Journal for ImmunoTherapy of Cancer",
issn = "2051-1426",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Immunotherapy response evaluation with magnetic resonance elastography (MRE) in advanced HCC

AU - Qayyum, Aliya

AU - Hwang, Ken Pin

AU - Stafford, Jason

AU - Verma, Anuj

AU - Maru, Dipen M.

AU - Sandesh, Subramanya

AU - Sun, Jia

AU - Pestana, Roberto Carmagnani

AU - Avritscher, Rony

AU - Hassan, Manal M.

AU - Amin, Hesham

AU - Rashid, Asif

AU - Wistuba, Ignacio I.

AU - Ehman, Richard L.

AU - Ma, Jingfei

AU - Kaseb, Ahmed O.

PY - 2019/11/28

Y1 - 2019/11/28

N2 - Background: Currently, there are no imaging predictors of immunotherapy outcome in hepatocellular carcinoma (HCC). The study aim was to determine if stiffness changes measured by magnetic resonance elastography (MRE) can be a predictor of immunotherapy response in patients with advanced HCC. Materials and methods: This was a prospective study of 15 patients with biopsy proven-advanced HCC treated with Pembrolizumab. All patients had liver MRE and liver biopsy at baseline and at 6 weeks of therapy. Change in HCC stiffness on MRE was compared with overall survival (OS), time to disease progression (TTP), and number of intratumoral CD3+ T lymphocytes. Analysis was performed using descriptive statistics and Spearman correlation (R); p-value < 0.05 was considered statistically significant. Results: Nine patients were evaluable. Median age was 71 years (range, 54-78). Etiology of liver disease was HCV (n = 4), HBV (n = 1) and NASH (n = 4). Median OS and TTP were 44 weeks and 13 weeks, respectively. Average baseline HCC stiffness and change in HCC stiffness were 5.0 kPa and 0.12 kPa, respectively. In contrast, average non-tumor liver stiffness was 3.2 kPa, and did not significantly change at 6 weeks (p = 0.42). Average size of measured tumor and change in size were 4 cm and - 0.32 cm, respectively. Change in HCC stiffness at 6 weeks correlated significantly with OS (R = 0.81), and TTP (R = 0.88,p < 0.01). Abundance of intratumoral T lymphocytes on tumor biopsy correlated significantly with HCC stiffness (R = 0.79,p = 0.007). Conclusion: Our pilot MRE data suggests early change in tumor stiffness may be an indicator of immunotherapy response in patients with advanced HCC.

AB - Background: Currently, there are no imaging predictors of immunotherapy outcome in hepatocellular carcinoma (HCC). The study aim was to determine if stiffness changes measured by magnetic resonance elastography (MRE) can be a predictor of immunotherapy response in patients with advanced HCC. Materials and methods: This was a prospective study of 15 patients with biopsy proven-advanced HCC treated with Pembrolizumab. All patients had liver MRE and liver biopsy at baseline and at 6 weeks of therapy. Change in HCC stiffness on MRE was compared with overall survival (OS), time to disease progression (TTP), and number of intratumoral CD3+ T lymphocytes. Analysis was performed using descriptive statistics and Spearman correlation (R); p-value < 0.05 was considered statistically significant. Results: Nine patients were evaluable. Median age was 71 years (range, 54-78). Etiology of liver disease was HCV (n = 4), HBV (n = 1) and NASH (n = 4). Median OS and TTP were 44 weeks and 13 weeks, respectively. Average baseline HCC stiffness and change in HCC stiffness were 5.0 kPa and 0.12 kPa, respectively. In contrast, average non-tumor liver stiffness was 3.2 kPa, and did not significantly change at 6 weeks (p = 0.42). Average size of measured tumor and change in size were 4 cm and - 0.32 cm, respectively. Change in HCC stiffness at 6 weeks correlated significantly with OS (R = 0.81), and TTP (R = 0.88,p < 0.01). Abundance of intratumoral T lymphocytes on tumor biopsy correlated significantly with HCC stiffness (R = 0.79,p = 0.007). Conclusion: Our pilot MRE data suggests early change in tumor stiffness may be an indicator of immunotherapy response in patients with advanced HCC.

KW - Hepatocellular carcinoma

KW - Immunotherapy

KW - Magnetic resonance Elastopgraphy

UR - http://www.scopus.com/inward/record.url?scp=85075801894&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85075801894&partnerID=8YFLogxK

U2 - 10.1186/s40425-019-0766-y

DO - 10.1186/s40425-019-0766-y

M3 - Article

C2 - 31779702

AN - SCOPUS:85075801894

VL - 7

JO - Journal for ImmunoTherapy of Cancer

JF - Journal for ImmunoTherapy of Cancer

SN - 2051-1426

IS - 1

M1 - 329

ER -